Exopharm Balance Sheet Health
Financial Health criteria checks 3/6
Exopharm has a total shareholder equity of A$4.1M and total debt of A$1.5M, which brings its debt-to-equity ratio to 37.2%. Its total assets and total liabilities are A$5.9M and A$1.8M respectively.
Key information
37.2%
Debt to equity ratio
AU$1.53m
Debt
| Interest coverage ratio | n/a |
| Cash | AU$1.64m |
| Equity | AU$4.13m |
| Total liabilities | AU$1.75m |
| Total assets | AU$5.88m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: EX1's short term assets (A$4.6M) exceed its short term liabilities (A$1.7M).
Long Term Liabilities: EX1's short term assets (A$4.6M) exceed its long term liabilities (A$39.7K).
Debt to Equity History and Analysis
Debt Level: EX1 has more cash than its total debt.
Reducing Debt: EX1's debt to equity ratio has increased from 0% to 37.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EX1 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: EX1 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 19.8% each year